{"id":164068,"date":"2022-02-16T11:11:07","date_gmt":"2022-02-16T03:11:07","guid":{"rendered":"http:\/\/www.namnewsnetwork.org\/?p=164068"},"modified":"2022-02-16T11:11:07","modified_gmt":"2022-02-16T03:11:07","slug":"moderna-to-set-up-new-subsidiary-in-malaysia","status":"publish","type":"post","link":"http:\/\/namnewsnetwork.org\/?p=164068","title":{"rendered":"Moderna To Set Up New Subsidiary In Malaysia"},"content":{"rendered":"\n<p>KUALA LUMPUR, Feb 16 (NNN-Bernama) &#8212; Biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines Moderna, Inc. on Wednesday announced plans to establish a new subsidiary in Malaysia, alongside three additional subsidiaries in Taiwan, Singapore, and Hong Kong.<\/p>\n\n\n\n<p>This announcement builds on Moderna\u2019s existing presence in the region, with offices in Japan, South Korea, and Australia, and demonstrates the company\u2019s continued commitment to the Asia-Pacific region as an essential part of its long-term strategy and commercial vision.<\/p>\n\n\n\n<p>\u201cWe are delighted to announce a future subsidiary to help deliver mRNA solutions to the people of Malaysia,\u201dsaid St\u00e9phane Bancel, chief executive officer of Moderna in a statement.<\/p>\n\n\n\n<p>\u201cMalaysia is a growing player in the pharmaceutical and biotech industry, and we look forward to exploring opportunities for local collaboration as Moderna expands its footprint in the Asia-Pacific region. I am excited to build strong teams that can deliver on the potential this region and our mRNA platform has to offer.\u201d<\/p>\n\n\n\n<p>Moderna\u2019s plan to establish a local subsidiary reflects its confidence in the current growth trajectory of Malaysia\u2019s pharmaceutical and healthcare industries.<\/p>\n\n\n\n<p>The company is further encouraged by the local government\u2019s commitment to biotech research and development. It is actively recruiting a team to build a strong presence in the market as its mRNA therapeutics pipeline grows, he said.<\/p>\n\n\n\n<p>Moderna\u2019s broader pipeline currently includes 40 development programmes, of which 25 are in clinical trials. The company continues to update its COVID-19 strategy to address variants of concern such as Omicron and pioneer new vaccines and therapeutics for a range of diseases and conditions.<\/p>\n\n\n\n<p>It is developing mRNA medicines to potentially prevent and treat diseases with significant unmet needs across infectious diseases, immuno-oncology, rare and ultra-rare diseases, and autoimmune diseases.<\/p>\n\n\n\n<p>The company has a presence in 12 markets globally. Regulators have approved Moderna\u2019s COVID-19 vaccine in more than 70 markets, including at least 19 in the Asia-Pacific region. In August 2021, Malaysia\u2019s Ministry of Health granted Moderna\u2019s COVID-19 vaccine conditional approval for emergency use.<\/p>\n\n\n\n<p>&#8212; NNN-BERNAMA<\/p>\n","protected":false},"excerpt":{"rendered":"<p>KUALA LUMPUR, Feb 16 (NNN-Bernama) &#8212; Biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines Moderna, Inc. on Wednesday announced plans to establish a new subsidiary in Malaysia, alongside three additional subsidiaries in Taiwan, Singapore, and Hong Kong. This announcement builds on Moderna\u2019s existing presence in the region, with offices in Japan, South Korea, and [&hellip;]<\/p>\n","protected":false},"author":30,"featured_media":164070,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[215,288,300,318],"tags":[],"_links":{"self":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/164068"}],"collection":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/users\/30"}],"replies":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=164068"}],"version-history":[{"count":0,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/164068\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/media\/164070"}],"wp:attachment":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=164068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=164068"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=164068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}